Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Marc Goodman

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Investors Business Daily

Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug

Biohaven shares plunged Thursday after the Food and Drug Administration unexpectedly delayed the review date for its rare-disease drug.

Investors Business Daily

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025.

Investors Business Daily

The $660 Million Opportunity That's Driving IBD Stock Of The Day Neurocrine Biosciences Higher

Neurocrine is Tuesday's IBD Stock Of The Day. After it unveiled promising results for a genetic disease drug, NBIX stock is on the rise.

Investors Business Daily

Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High

Acadia obliterated expectations for the launch quarter of its Rett syndrome treatment and, on Friday, ACAD stock hit a two-year high.

Investors Business Daily

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment

Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock briefly above its 50-day line Tuesday.

Investors Business Daily

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Benzinga

How These Biotech Players Could Help Treat Covid-Fueled Depression

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Investors Business Daily

Can IBD Stock Of The Day Neurocrine Biosciences Leapfrog Rivals For A $13 Billion Shot?

Neurocrine is the IBD Stock Of The Day. The biotech stock is approaching two potential entries as the movement disorder space heats up.

Investors Business Daily

Amylyx Stock Jumps As FDA Mulls ALS Drug — What To Know Ahead Of FDA Action

IPO stock Amylyx Pharmaceuticals surged Friday ahead of an important Food and Drug Administration meeting to discuss its ALS treatment.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

the Food and Drug Administration

Neurocrine Biosciences

ACADIA Pharmaceuticals

Amylyx Pharmaceuticals

18 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.